Concepedia

Author

Stefan Walzer

Roche (Switzerland)ORCID

Also Known As

S Walzer, S. Irvin Walzer, S. Walzer, Stefan WALZER, Stefan Walzer, Walzer S, Walzer, Stefan

274

Publications

1.5K

Citations

19

H-Index

46

Concepts

All Affiliations

Roche (Switzerland)LungenClinic GrosshansdorfSorbonne UniversitéHôpital Saint-AntoineHospital Universitario La Paz
SW

About

Stefan Walzer is an author at Roche (Switzerland) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

202

2

Engineering

5

5

75

3

Computer Science

4

4

65

4

Public Health

1

1

28

5

Computer Engineering

1

1

21

Stefan Walzer

×

33

Publications

899

Citations

17

H-Index

YearCitations

'Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting'

Andrew Palmer, S Roze, Valentine Wn,

eCite Digital Repository (University of Tasmania)

2007

199

Economic evaluation of individualized nutritional support in medical inpatients: Secondary analysis of the EFFORT trial

Philipp Schüetz, Suela Sulo, Stefan Walzer,

Clinical Nutrition

2020

82

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

G. Mickisch, M. Gore, Bernard Escudier,

British Journal of Cancer

2009

66

Development and Validation of the Economic Assessment of Glycemic Control and Long-Term Effects of Diabetes (EAGLE) Model

Elvira Mueller, Stefanie Maxion‐Bergemann, Dmitry Gultyaev,

Diabetes Technology & Therapeutics

2006

56

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Kurt Banz, Helge Bischoff, Matthias Brunner,

Lung Cancer

2011

34

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

Stefan Walzer, Clemente Ponzetti, Monica Canciani,

ClinicoEconomics and Outcomes Research

2016

32

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

Giovanni Giuliani, Francesco Grossi, Filippo de Marinis,

Lung Cancer

2010

29

Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy

Francesco Grossi, Carlo Genova, Nidia Diaz Gaitan,

Lung Cancer

2013

28

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

A. Vergnenègre, Ray, C. Chouaïd,

ClinicoEconomics and Outcomes Research

2012

24

Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan

Myung‐Ju AHN, Chun-Ming Tsai, Te‐chun Hsia,

Asia-Pacific Journal of Clinical Oncology

2011

24

Page 1